Skip to Content

Join the 'Viberzi' group to help and get support from people like you.

Viberzi News

New IBS Drug Eases Stomach Pain and Diarrhea for Some: Study

Posted 21 Jan 2016 by Drugs.com

WEDNESDAY, Jan. 20, 2016 – A new drug for irritable bowel syndrome with diarrhea seems to reduce symptoms for some patients for at least six months, two clinical trials found. Based on these findings, the drug Viberzi (eluxadoline) was approved recently by the U.S. Food and Drug Administration. In the phase 3 trials, more than 30 percent of patients experienced improvement in their symptoms at least half of the time they were taking the drug. This compared to about a 20 percent improvement in those taking a placebo, the study authors said. "This drug offers another option for patients who have IBS (irritable bowel syndrome) with diarrhea who have not found relief with currently available treatment," said lead researcher Dr. Anthony Lembo, an associate professor of medicine at Harvard Medical School in Boston. This drug, taken twice daily, should only be used for IBS with diarrhea as ... Read more

Related support groups: Diarrhea, Irritable Bowel Syndrome, Diarrhea, Chronic, Viberzi, Eluxadoline

Two Drugs Approved for Irritable Bowel

Posted 1 Jun 2015 by Drugs.com

THURSDAY, May 28, 2015 – Two new therapies to treat irritable bowel syndrome accompanied by diarrhea (IBS-D) in adults have been approved by the U.S. Food and Drug Administration. IBS, characterized by loose stools and abdominal discomfort, affects 10 percent to 15 percent of U.S. adults, the FDA said in a news release. The first drug, Viberzi, is taken twice daily with food. It stimulates nervous system receptors that can reduce bowel contractions. Common side effects include constipation, nausea and abdominal pain. The most serious adverse reaction is a type of muscular spasm that can lead to pancreatitis, the FDA said. The second drug, Xifaxan, is taken orally three times daily for 14 days. And people with recurring symptoms can take a second 14-day dose if needed, the agency said. It was approved previously as an antibiotic to treat certain cases of "traveler's diarrhea." It's also ... Read more

Related support groups: Irritable Bowel Syndrome, Xifaxan, Rifaximin, Viberzi, Eluxadoline

FDA Approves New Drugs for Irritable Bowel Syndrome

Posted 1 Jun 2015 by Drugs.com

THURSDAY, May 28, 2015 – Two new drugs for adults with irritable bowel syndrome with diarrhea (IBS-D) were approved by the U.S. Food and Drug Administration on Wednesday. "For some people, IBS can be quite disabling, and no one medication works for all patients suffering from this gastrointestinal disorder," Dr. Julie Beitz, director of the Office of Drug Evaluation III in FDA's Center for Drug Evaluation and Research, said in an agency news release. "The approval of two new therapies underscores the FDA's commitment to providing additional treatment options for IBS patients and their doctors," she added. Viberzi (eluxadoline) is a pill that contains a new type of active ingredient, and it is taken twice a day with food. It is designed to activate receptors in the nervous system that can lessen bowel contractions. Xifaxan (rifaximin) is a pill taken three times a day for 14 days to ... Read more

Related support groups: Irritable Bowel Syndrome, Xifaxan, Rifaximin, Viberzi, Eluxadoline

FDA Approves Two Therapies to Treat Irritable Bowel Syndrome with Diarrhea (IBS-D)

Posted 28 May 2015 by Drugs.com

May 27, 2015 – The U.S. Food and Drug Administration today approved Viberzi (eluxadoline) and Xifaxan (rifaximin), two new treatments, manufactured by two different companies, for irritable bowel syndrome with diarrhea (IBS-D) in adult men and women. According to the National Institutes of Health, patients with irritable bowel syndrome (IBS) experience a number of signs and symptoms, including pain or discomfort in the abdomen and changes in bowel movement patterns. Studies estimate that IBS affects 10 to 15 percent of adults in the United States. IBS-D is a subtype characterized mainly by loose or watery stools at least 25 percent of the time. “For some people, IBS can be quite disabling, and no one medication works for all patients suffering from this gastrointestinal disorder,” said Julie Beitz, M.D., director of the Office of Drug Evaluation III in FDA’s Center for Drug Evalu ... Read more

Related support groups: Irritable Bowel Syndrome, Xifaxan, Rifaximin, Viberzi, Eluxadoline

FDA Approves Viberzi (eluxadoline) for Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults

Posted 27 May 2015 by Drugs.com

DUBLIN, May 27, 2015 /PRNewswire/ – Actavis plc (NYSE: ACT) announced today that Viberzi (eluxadoline) was approved by the Food and Drug Administration (FDA) as a twice-daily, oral treatment for adults suffering from irritable bowel syndrome with diarrhea (IBS-D). Viberzi (eluxadoline) has mixed opioid receptor activity, it is a mu receptor agonist, a delta receptor antagonist, and a kappa receptor agonist. "The FDA's approval of Viberzi is the first step to providing physicians with a new, evidence-based, treatment option for their adult patients with IBS-D," said David Nicholson, Executive Vice President, Actavis Global Brands R&D. "At Actavis, we are dedicated to providing new treatment options, and the development of new agents that help address the most bothersome symptoms of IBS-D. We are very pleased to be working with the FDA to advance this IBS-D treatment and we eagerly ... Read more

Related support groups: Irritable Bowel Syndrome, Viberzi, Eluxadoline

Ask a Question

Further Information

Related Condition Support Groups

Irritable Bowel Syndrome

Viberzi Patient Information at Drugs.com